Psychological distress related to BRCA testing in ovarian cancer patients

被引:24
作者
Bjornslett, Merete [1 ,2 ]
Dahl, Alv A. [2 ,3 ]
Sorebo, Oystein [4 ]
Dorum, Anne [5 ]
机构
[1] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Mol Oncol, N-0424 Oslo, Norway
[2] Univ Oslo, Fac Med, Oslo, Norway
[3] Oslo Univ Hosp, Norwegian Radium Hosp, Natl Advisory Ctr Late Effects Canc Treatment, Dept Oncol, Oslo, Norway
[4] Buskerud & Vestfold Univ Coll, Sch Business & Social Sci, Honefoss, Norway
[5] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Gynecol Oncol, Oslo, Norway
关键词
Ovarian cancer; Oncology; BRCA; MICRA; Anxiety; HEREDITARY BREAST; DEPRESSION SCALE; HOSPITAL ANXIETY; RISK; QUESTIONNAIRE; MUTATIONS; DESIGN; IMPACT; WOMEN;
D O I
10.1007/s10689-015-9811-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An increasing demand for genetic testing has moved the procedure from highly selected at-risk individuals, now also including cancer patients for treatment associated testing. The heritable fraction of ovarian cancer is more than 10 %, and our department has offered BRCA testing to such patients irrespective of family history since 2002. This study examined potential psychosocial distress associated with this procedure using The Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire and other patient-rated generic distress instruments. Patients were divided into four groups according to cancer risk: mutation carriers, own history of breast cancer and ovarian cancer, family history of breast cancer and/or ovarian cancer, and patients without family history. In a postal survey, 354 patients responded. Good acceptance of the MICRA was observed, and previously described good psychometric properties were confirmed. A significant association between MICRA total score and receiving a positive BRCA test result was found. No significant between-group differences were observed with generic distress instruments. Time since cancer diagnosis, test result, and survey showed no significant associations with MICRA scores. Internal consistencies of instruments were adequate. Exploratory and confirmatory factor analyses showed adequate fit indices for a three factor solution of the MICRA, but further refinement of the items should be considered. In conclusion, the specific types of worry and distress most relevant to receiving genetic testing irrespective of family history were not captured by the generic distress instruments. The MICRA was supported as a useful tool for detection of mental distress related to genetic testing and risk evaluation.
引用
收藏
页码:495 / 504
页数:10
相关论文
共 50 条
  • [31] Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients
    Pinto, Carmine
    Bella, Maria Angela
    Capoluongo, Ettore
    Carrera, Paola
    Clemente, Claudio
    Colombo, Nicoletta
    Cortesi, Laura
    De Rosa, Gaetano
    Fenizia, Francesca
    Genuardi, Maurizio
    Gori, Stefania
    Guarneri, Valentina
    Marchetti, Antonio
    Marchetti, Paolo
    Normanno, Nicola
    Pasini, Barbara
    Pignata, Sandro
    Radice, Paolo
    Ricevuto, Enrico
    Russo, Antonio
    Tagliaferri, Pierosandro
    Tassone, Pierfrancesco
    Truini, Mauro
    Varesco, Liliana
    FUTURE ONCOLOGY, 2016, 12 (18) : 2071 - 2075
  • [32] Temporal Patterns and Adoption of Germline and Somatic BRCA Testing in Ovarian Cancer
    Huepenbecker, Sarah P.
    Wright, Jason D.
    Downer, Mary K.
    Incerti, Devin
    Luhn, Patricia
    Dolado, Ignacio
    Bastiere-Truchot, Lydie
    Lin, Yvonne G.
    Chan, John K.
    Meyer, Larissa A.
    OBSTETRICS AND GYNECOLOGY, 2022, 140 (05) : 758 - 767
  • [33] Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2
    Metcalfe, K. A.
    Poll, A.
    Llacuachaqui, M.
    Nanda, S.
    Tulman, A.
    Mian, N.
    Sun, P.
    Narod, S. A.
    CLINICAL GENETICS, 2010, 78 (05) : 411 - 417
  • [34] FLABRA, frontline approach for BRCA testing in an ovarian cancer population: a Latin America epidemiologic study
    Giornelli, Gonzalo
    Gallardo, Dolores
    Hegg, Roberto
    Abuin, Gonzalo Gomez
    La Vega, Maximo De
    Lim-Law, Maria
    Caceres, Valeria
    Trujillo, Lina
    Pilar Estevez-Diz, Maria del
    Pacheco, Cristian
    Sganga, Leonardo
    Goncalves, Susana
    FUTURE ONCOLOGY, 2021, 17 (13) : 1601 - 1609
  • [35] Comparison of effectiveness of treatment of patients with sporadic and germline BRCA1-related ovarian cancer
    Szatkowski, Wiktor
    Muzykiewicz, Konrad
    Jasiowka, Marek
    Karolewski, Kazimierz
    Kojs, Zbigiew
    Klimek, Malgorzata
    Blecharz, Pawel
    GINEKOLOGIA POLSKA, 2016, 87 (06) : 422 - 425
  • [36] Assessment of psychological distress in cancer patients: a pivotal role for clinical interview
    Bonacchi, A.
    Rossi, A.
    Bellotti, L.
    Franco, S.
    Toccafondi, A.
    Miccinesi, G.
    Rosselli, M.
    PSYCHO-ONCOLOGY, 2010, 19 (12) : 1294 - 1302
  • [37] BRCA mutations: Implications of genetic testing in ovarian cancer
    Talwar, Vineet
    Rauthan, Amit
    INDIAN JOURNAL OF CANCER, 2022, 59 : S56 - S67
  • [38] BRCA1 and BRCA2 Genetic Testing in Breast and/or Ovarian Cancer Families in Iran
    Keshavarzi, Fatemeh
    Javadi, Gholam Reza
    Nafissi, Nahid
    Akbari, Mohammad Esmail
    Yassaee, Vahid Reza
    Farzad, Maryam Sharafi
    Zeinali, Sirous
    YAKHTEH, 2010, 12 (03): : 329 - 340
  • [39] Age at Diagnosis May Trump Family History in Driving BRCA Testing in a Population of Breast Cancer Patients
    Vig, Hetal S.
    McCarthy, Anne Marie
    Liao, Kaijun
    Demeter, Mirar Bristol
    Fredericks, Tracey
    Armstrong, Katrina
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2013, 22 (10) : 1778 - 1785
  • [40] Psychological distress and decision-making factors for prophylactic bilateral mastectomy in cancer-unaffected BRCA1/2 pathogenic variant carriers
    Isselhard, Anna
    Tuchler, Anja
    Dick, Julia
    Scherer, Anne
    Aue, Viktoria
    Schmutzler, Rita K.
    Rhiem, Kerstin
    PSYCHO-ONCOLOGY, 2023, 32 (04) : 640 - 648